# Inivata

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inivata

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.inivata.com
- Total disclosed funding: $139M
- Latest round: Series C (Feb 4, 2021)
- Investors on record: 9

## About

Based in Cambridge, United Kingdom, and founded in 2014, Inivata Ltd. is a developer of liquid biopsy. The company was co-founded by Clive Morris, Davina Gale, James Brenton, Nitzan Rosenfeld, and Tim Forshew. Inivata Ltd. has a CLIA certified, CAP-accredited laboratory in Research Triangle Park, NC, and Research Development (R&D) laboratories in Cambridge, UK. In 2016, the company won a One Nucleus BioNewsRound Award at Genesis Conference. In February 2021, Inivata Ltd. raised its latest series C funding from Soleus Capital. In May 2021, the company was acquired by NeoGenomics, Inc.

Inivata operates as a liquid biopsy platform that offers Non-invasive ctDNA analysis for describing the process of extracting a small blood sample from a patient, Circulating Tumor DNA intended to represent the release of ctDNA into the bloodstream by a tumor, and Radar for the detection of residual disease and recurrence. The company provides InVisionFirst-Lung, a genomic test administered using blood plasma from Non-Small Cell Lung Cancer (NSCLC) patients, and InVisionSeq, another genomic sequencing test.

Inivata Ltd. plans to use its latest series C funding to build a clinical development program that will bring the benefits of RaDaR to patients more directly. In addition, the proceeds will drive the continued commercial rollout of Inivata’s InVisionFirst®-Lung liquid biopsy test.

## Funding rounds

- Series C, Feb 4, 2021, $35M — Longview Innovation, Farallon Capital Management, Janus Henderson Investors, Soleus Capital
- Series B, Mar 28, 2019, $53M — Johnson & Johnson Innovation, Longview Innovation, Cambridge Innovation Capital, Woodford Patient Capital Trust, RT Ventures
- Series A, Jan 26, 2016, $45M — Johnson & Johnson Innovation, Touchstone Innovations, Cambridge Innovation Capital
- Seed, Sep 23, 2014, $6.5M — Johnson & Johnson Innovation, Touchstone Innovations, Cambridge Innovation Capital

## Investors

- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Seed, Series A, Series B
- Touchstone Innovations (https://capitalatlas.ai/funds/touchstone-innovations) — Seed, Series A
- Cambridge Innovation Capital (https://capitalatlas.ai/funds/cambridge-innovation-capital) — Seed, Series A, Series B
- Longview Innovation (https://capitalatlas.ai/funds/longview-innovation) — Series B, Series C
- Woodford Patient Capital Trust — Series B
- RT Ventures — Series B
- Farallon Capital Management (https://capitalatlas.ai/funds/farallon-capital-management) — Series C
- Janus Henderson Investors — Series C
- Soleus Capital (https://capitalatlas.ai/funds/soleus-capital) — Series C